All In Biotech

Drug Trial Radar · NCT06564194

A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSV

A Phase 1 Randomized, Double-Blinded Study to Assess the Safety, Reactogenicity and Immunogenicity of JCXH-108, an mRNA-based Investigational Vaccine Against Respiratory Syncytial Virus (RSV) in Healthy Subjects ≥ 60 Years of Age and 18-45 Years of Age

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

75

Actual

Start

Sep 25, 2024

Primary completion

Dec 12, 2024

Study completion Dec 30, 2026

Sponsor

Lead sponsor
Immorna Biotherapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
Tigermed Consulting Co., Ltd
First posted
Aug 21, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to assess the safety, reactogenicity and immunogenicity of an mRNA-based vaccine, JCXH-108, the prevention of Respiratory Syncytial Virus (RSV) infection and diseases. Participants will be randomized to receive either JCXH-108 or placebo.

Conditions

  • Respiratory Syncytial Virus (RSV)
  • Infectious Disease

Interventions

  • JCXH-108Biological

    IM injection

  • PlaceboOther

    IM injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SAE FrequencyTime frame: Day 1 - Day 180 (6 Months)
  2. Injection site reactionTime frame: Day 1 - Day 30
  3. Solicited systemic reaction frequencyTime frame: Day 1 - Day 30
  4. AE frequencyTime frame: Day 1 -Day 30
  5. Medically attended AE frequencyTime frame: Day 1 - Day 180 (6 Months)
  6. Potential immune-mediated adverse events frequencyTime frame: Day 1 - Day 180 (6 Months)

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Health Awareness

    Jupiter, Florida

  • DelRicht - New Orleans

    New Orleans, Louisiana

  • Sundance Clinical Research

    St Louis, Missouri

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.